AMR

Authors: Kiggwe A, Nalwanga D, Tagoola A, Madhi S, Moore PD, Archary M, Mulenga V, Mujuru AH, Sacarlal J, Buck WC, Sidat M, Nguyen H, Haque F, Dennis E, Clements M, Murphy B, Spittle B, Viero F, Bielicki J, Musiime V,  Sharland M

Presented at: The EDCTP Forum 2023

Authors: Pillay K, Archary M, Bielicki J, Buck WC, Clements M, Dennis E, Goelen J, Haque F, Kiggwe A, Madhi S, Moore PD, Mujuru AH, Mulenga V, Murphy B, Musiime V, Nalwanga D, Nguyen H, Sacarlal J, Sidat M, Spittle B, Tagoola A, Viero F, Sharland M

Presented at: The EDCTP Forum 2023

Authors: Sacarlal WJ, Buck C, Passanduca A, Macassa E, Saíde A, Chhaganlal K, Gafur M, Seni A, Machava S, Martins L, Issa F, Macanze E, Manjate N, Chaúque S, Langa S, Sidat M, Cassia U, Salimo A, Mavume C, Massitela C, Maieca A, Joaquim W, Martins S, Adriano Q, Zandamela M, Bramugy J, Bassat Q, Moraleda C, Tagarro A, Sharland M, Rojo P

Presented at: The EDCTP Forum 2023

Authors: Moore PD, Waggie Z, Nkosi S, Nkosi L, Kumalo N, Nkumana N, Zulu N, Dangor Z, Sharland M, Madhi S

Presented at: The EDCTP Forum 2023

The European Medicines Agency (EMA) has published the final revised guideline on the evaluation of human medicines for the treatment of bacterial infections.

The revised guideline reflects the outcome of recent discussions between regulators in the EU, United States and Japan on the development of new antimicrobial medicines. Among others, it includes recommendations on the clinical criteria for patient enrolment, the primary endpoint and the primary analysis in infection site-specific trials.

We are pleased to announce that the PediCAP trial have successfully passed its 25% recruitment milestone with more than 400 patients successfully randomised into their arms. PediCAP will determine whether children hospitalised for severe or very severe pneumonia, do better on co-amoxiclav or amoxicillin oral step-down therapy and how long these children should continue to receive antibiotic treatment.

Currently, the WHO recommends that children with severe or very severe pneumonia receive injectable antibiotics for at least five days as these antibiotics cover a wide range of bacterial pathogens than oral amoxicillin alone.

NeoIPC, a project seeking to reduce the transmission of resistant bacteria in neonatal intensive care units, has just launched.

Nearly 1 in 10 newborns in Europe is admitted to a neonatal intensive care unit (NICU) in the first days of life, around 400,000 admissions every year. In low and middle-income countries, the rate of hospital births is increasing, with more critically ill infants being cared for in dedicated care units.

We are proud to announce that on the 7th of December 2020, the PediCAP team at Makerere University at the China-Uganda Friendship Hospital Naguru (Kampala, Uganda) recruited the very first participant into the PediCAP clinical trial.

Though the study experienced a delayed start due to the COVID-19 pandemic, the drive and commitment of the Ugandan team ensured all ethical and regulatory approvals were acquired by June 2020,

The World Health Organization (WHO) and the Global Sepsis Alliance (GSA) will host a co-organized World Sepsis Congress Spotlight. This free online event aims to review achievements, challenges, and potential solutions to combat the threat of sepsis worldwide.

On September 9^th, the WHO and the Global Sepsis Alliance (GSA) will co-host the free online congress “WSC Spotlight Sepsis. Pandemics, and Antimicrobial Resistance – Global Health Threats of the 21st Century”.

Through 6 distinctive sessions, the WSC Spotlight will give an overview of the global epidemiology and burden of sepsis and AMR, exploring innovative, novel, and cost-effective approaches for the prevention and treatment of both severe infections and antimicrobial resistance.

Authors: Hill LF, Turner MA, Lutsar I, et al; NeoVanc Consortium.

Published in: Trials. 2020;21(1):329

Aislinn Cook, a research fellow at St. George’s University of London in the Paediatric Infectious Diseases Research Group, is the winner of the ISF/ESCMID Sepsis Award 2020! The International Sepsis Forum (ISF) is a non-profit public American charity with the mission to improve outcomes for patients with sepsis. Aislinn was awarded this prize for her ECCMID2020 abstract on the NeoAMR Global Neonatal Sepsis Observational Study (NeoOBS).

Authors: Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M

Published in: Antimicrob Resist Infect Control.2020;9:3

Background Antibiotics are the most common medicines prescribed to children in hospitals and the community, with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises healthcare costs, and selection of resistance.

Authors: Folgori L, Lutsar I, Standing JF, et al.

Published in: BMJ Open. 2019; 9:e032592

Today, 18th of November, is European Antibiotic Awareness Day (EADD), that marks the start of the World Antibiotic Awareness Week (WAAW). WAAW aims to increase global awareness of antibiotic resistance, as well as  encourage best practices among the general public, health workers and policy makers to stop the spread of antibiotic resistance. The latest data from the European Centre for Disease Prevention and Control highlights that across the European Union,

Bacteria are steadily becoming less and less responsive to currently available antibiotics. Together with members of the public, we explored the hot topic of ‘antimicrobial resistance’ at the European Researchers’ Night on 27 September 2019 in Padua, Italy. Every year in the EU alone, an estimated 33,000 people die as a result of infections that cannot be treated with antimicrobial drugs. Sure enough, the World Health Organization (WHO) has placed the growth of antimicrobial resistance on its list of top five threats to global health in 2019.

Penta will be at the European Researchers’ Night in Padua on 27 September, 2019. For this edition we have chosen the theme of ‘antimicrobial resistance’ (AMR). With the help of flyers and an educational video we hope to illustrate to the public what ‘AMR’ is, how it develops and spreads, and raise awareness on how much this problem is threatening global health.